Skip to main content
Premium Trial:

Request an Annual Quote

Axela, Thermal Gradient Ink Deal for Technology Integration

NEW YORK (GenomeWeb News) – Axela today announced a development deal to integrate Thermal Gradient's rapid PCR technology into Axela's Flow-Thru Chip automated workflow.

Initially, Thermal Gradient's technology will added to Axela's patent pending approach for capturing and quantifying targeted nucleic acids. The workflow is now optimized for formalin-fixed, paraffin-embedded tissue and is designed for use with other specimens, including other biopsy samples, blood, and isolated cells.

Axela's Flow-Thru Chip platform is meant for researchers who need technology to address the gap between multiplexed PCR and high density DNA/RNA arrays, the Toronto-based firm said.

"Our technology enables us to design inexpensive devices that perform PCR in just a few minutes," Robert Juncosa, CEO of Rochester, NY-based Thermal Gradient, said in a statement. "It is our business model to adapt our PCR and other sample preparation capabilities to a partner's application. The integration of our technology with Axela's Flow-Thru Chip rapid hybridization and detection capabilities will provide a powerful automated solution for the broad markets that benefit from higher multiplex analysis."

Financial and other terms of the deal were not disclosed.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.